Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
Tivic Health (Nasdaq: TIVC), a diversified therapeutics company focused on immune and autonomic nervous systems, has scheduled its 2024 year-end financial results announcement for March 21, 2025. The results will be presented through a pre-recorded conference call and webcast at 1:30 PM PT / 4:30 PM ET.
Investors can access the teleconference via toll-free number 1-877-407-0779 (International: 1-201-389-0914) using Conference ID 13752399, or through the webcast link provided.
Tivic Health (Nasdaq: TIVC), un'azienda terapeutica diversificata focalizzata sui sistemi immunitario e nervoso autonomo, ha programmato l'annuncio dei risultati finanziari di fine anno per il 21 marzo 2025. I risultati saranno presentati tramite una conferenza telefonica pre-registrata e un webcast alle 13:30 PT / 16:30 ET.
Gli investitori possono accedere alla teleconferenza tramite il numero verde 1-877-407-0779 (Internazionale: 1-201-389-0914) utilizzando l'ID conferenza 13752399, o tramite il link del webcast fornito.
Tivic Health (Nasdaq: TIVC), una compañía terapéutica diversificada centrada en los sistemas inmunológico y nervioso autónomo, ha programado el anuncio de sus resultados financieros de fin de año para el 21 de marzo de 2025. Los resultados se presentarán a través de una conferencia telefónica pregrabada y un webcast a la 1:30 PM PT / 4:30 PM ET.
Los inversores pueden acceder a la teleconferencia a través del número gratuito 1-877-407-0779 (Internacional: 1-201-389-0914) utilizando el ID de conferencia 13752399, o a través del enlace del webcast proporcionado.
Tivic Health (Nasdaq: TIVC)는 면역 및 자율 신경계에 중점을 둔 다각화된 치료 회사로, 2024년 연말 재무 결과 발표를 2025년 3월 21일로 예정하고 있습니다. 결과는 사전 녹음된 전화 회의와 웹캐스트를 통해 오후 1시 30분 PT / 오후 4시 30분 ET에 발표될 예정입니다.
투자자는 무료 전화번호 1-877-407-0779(국제: 1-201-389-0914)로 전화 회의에 접속할 수 있으며, 회의 ID 13752399를 사용하거나 제공된 웹캐스트 링크를 통해 접속할 수 있습니다.
Tivic Health (Nasdaq: TIVC), une entreprise thérapeutique diversifiée axée sur les systèmes immunitaire et nerveux autonome, a programmé l'annonce de ses résultats financiers de fin d'année pour le 21 mars 2025. Les résultats seront présentés lors d'une conférence téléphonique préenregistrée et d'un webcast à 13h30 PT / 16h30 ET.
Les investisseurs peuvent accéder à la téléconférence via le numéro gratuit 1-877-407-0779 (International : 1-201-389-0914) en utilisant l'ID de conférence 13752399, ou via le lien de webcast fourni.
Tivic Health (Nasdaq: TIVC), ein diversifiziertes therapeutisches Unternehmen, das sich auf das Immunsystem und das autonome Nervensystem konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse zum Jahresende 2024 für den 21. März 2025 angesetzt. Die Ergebnisse werden über einen vorab aufgezeichneten Telefonkonferenz und Webcast um 13:30 Uhr PT / 16:30 Uhr ET präsentiert.
Investoren können über die gebührenfreie Nummer 1-877-407-0779 (international: 1-201-389-0914) auf die Telefonkonferenz zugreifen, indem sie die Konferenz-ID 13752399 verwenden, oder über den bereitgestellten Webcast-Link.
- None.
- None.
Teleconference Details:
Toll Free: 1-877-407-0779
International: 1-201-389-0914
Conference ID Code: 13752399
Webcast Link
https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39
About Tivic Health Systems, Inc.
Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health takes a multi-pronged approach to treating the root causes of diseases caused by immune dysregulation and dysautonomia. The combination of bioelectronic and biologic medicines allow Tivic to target disorders and disease via both neural pathways and molecular approaches.
Tivic Health’s first FDA approved product ClearUPTM is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https://ir.tivichealth.com
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health’s actual results to differ from those contained in the forward-looking statements, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313844754/en/
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.